Dabur shares in focus after US FDA places Silvassa plant products under import alert

Shares of Dabur India

Ltd. will be in focus on Friday, June 12, after the company said the US Food and Drug Administration (FDA) has placed certain products manufactured at its Silvassa facility under Import Alert 66-40.

In an exchange filing, Dabur said the US FDA issued the import alert on June 10, 2026, following its review of the company's responses and the Establishment Inspection Report (EIR) related to an earlier inspection of the plant located in Silvassa, Dadra and Nagar Haveli.

The regulator had inspected the facility and identified certain deficiencies related to data integrity and maintenance practices. Following the inspection, Dabur submitted its responses to the observations raised by the US FDA.

The company, however, said the import alert will have no material impact on its financials, operations or other business activities.

According to Dabur, the order pertains only to a small section of the Silvassa facility involved in the manufacture of private-label products, which contribute an insignificant portion of the company's revenue.

The company also clarified that its domestic products are not covered under the import alert and that the Silvassa plant continues to remain operational.

Dabur said it is continuing to engage with the US FDA and has submitted corrective and preventive action plans to address the identified gaps. The company added that multiple internal assessments and independent third-party tests have not identified any out-of-specification issues or other concerns related to its products.

The FMCG maker said it remains committed to maintaining product quality and consumer safety and is implementing alternative sourcing arrangements to ensure uninterrupted supplies to customers in the US market.

Addressing the timing of the disclosure, Dabur said there was no material delay in informing exchanges as the company was reviewing the regulator's order and evaluating the next course of action.

Dabur India shares ended Thursday's session 1.15% lower at ₹423. The stock has declined more than 15% so far in 2026.